Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
ProQR Therapeutics N.V. Ordinary Shares (PRQR), a clinical-stage biotech firm focused on RNA-based therapies for rare genetic diseases, is trading at $1.82 as of April 6, 2026, marking a 6.55% gain in recent trading. This analysis evaluates current price action, sector context, key technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available for the company as of this publication. The recent upward move comes amid mixed sentimen
Is ProQR (PRQR) Stock Good for Short Term | Price at $1.82, Up 6.55% - Take Profit Levels
PRQR - Stock Analysis
3112 Comments
1891 Likes
1
Coua
Loyal User
2 hours ago
Concise yet full of useful information β great work.
π 252
Reply
2
Makarius
Senior Contributor
5 hours ago
Are you trying to make the rest of us look bad? π
π 34
Reply
3
Bellamay
Regular Reader
1 day ago
That made me do a double-take. π
π 67
Reply
4
Tanaja
Trusted Reader
1 day ago
Ah, missed out again! π
π 280
Reply
5
Canaan
Expert Member
2 days ago
Clear explanations of market dynamics make this very readable.
π 32
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.